Market Overview

Rexahn Pharma Expands Intellectual Property Related to Class of Anti-Cancer Isoquinolinamine Compounds

Share:
Related RNN
Rexahn Pharmaceuticals Awarded Patent in Japan for Novel Targeted Cancer Drug Delivery Platform
Data on Rexahn's RX-3117 in Non-Small Cell Lung Cancer Presented at 16th International Symposium of the Purine and Pyrimidine Society

Rexahn Pharmaceuticals, Inc. (NYSE: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has significantly expanded its intellectual property (IP) around isoquinolinamine, a class of potent anti-cancer compounds. Rexahn has been issued a continuation patent US 8,314,123 for US 8,034,829 to cover more new isoquinolinamine compounds and their pharmaceutical composition and method for producing an anti-tumor effect.

Posted-In: News FDA

 

Related Articles (RNN)

Get Benzinga's Newsletters